Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Dermatologic 3Gastrointestinal 2CNS 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Colorectal Neoplasms 20Pancreatic Neoplasms 11Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Rectal Neoplasms 5Colonic Neoplasms 5Thyroid Neoplasms 4Multiple Myeloma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Neoplasm Metastasis 3Melanoma 3Hematologic Neoplasms 3Glioma 3Breast Neoplasms 3Bile Duct Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1

Interventions

pembrolizumab 36Magnetic Resonance Spectroscopy 23Gemcitabine 19Specimen Handling 15Nivolumab 12Carboplatin 12Surveys and Questionnaires 11Paclitaxel 11Cetuximab 11Early Intervention, Educational 10Bevacizumab 10Standard of Care 9Cyclophosphamide 9Cisplatin 9Radiosurgery 8Methods 8Fluorouracil 8Docetaxel 8Blood Specimen Collection 8Psychiatric Rehabilitation 7Pemetrexed 7sargramostim 6aldesleukin 6Taxes 6Injections 6Fluorodeoxyglucose F18 6Educational Status 6Drug Therapy 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × trametinib × Gastrointestinal × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔